Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial
(MedPage Today) -- Second-line treatment with an investigational anti-CTLA-4 immunotherapy improved survival in squamous non-small cell lung cancer (NSCLC) compared with chemotherapy, according to results of the phase III PRESERVE-003 trial. Among...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial medpagetoday.com
